German Genomics Company GPC Sees Revenues Double in 2000 | GenomeWeb

NEW YORK, March 16 - German Genomics company GPC Biotech said Friday its 2000 revenues more than doubled to 10.9 million euros ($9.8 million), compared with 4.3 million euros in 1999, as the company forged several new research alliances with companies such as Aventis, Boehringer Ingelheim, Altana, and Karo Bio.

In addition to performing contract genomics and proteomics research, the company is also developing an in-house pipeline for drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.